Objective. Systemic sclerosis (SSc) is characterized by fibrosis of the skin and visceral organs. Patients with SSc have enhanced plasma levels of the plasmin-␣2-antiplasmin (␣2AP) complex, and we recently implicated ␣2AP in the development of fibrosis through transforming growth factor  (TGF) production. This study was undertaken to clarify how ␣2AP induces TGF production and the development of fibrosis.Methods. To clarify the detailed mechanism by which ␣2AP induces TGF production, we focused on adipose triglyceride lipase (ATGL)/calcium-independent phospholipase A 2 (iPLA 2 ) and examined whether ATGL/ iPLA 2 is associated with ␣2AP-induced TGF production. The mouse model of bleomycin-induced SSc was used to evaluate the role of ␣2AP in the development of fibrosis. Dermal thickness and collagen content were determined in mouse skin treated with phosphate buffered saline or bleomycin. Moreover, we cultured SSclike fibroblasts from the bleomycin-treated mouse skin and examined the production of TGF and prostaglandin F 2␣ (PGF 2␣ ).Results. We found that ␣2AP binding to ATGL promoted PGF 2␣ synthesis through iPLA 2 in fibroblasts, and the PGF 2␣ synthesis that was promoted by ␣2AP induced TGF production in fibroblasts. In addition, the neutralization of ␣2AP attenuated the production of TGF and PGF 2␣ in SSc-like fibroblasts from mice. The ␣2AP deficiency attenuated bleomycininduced fibrosis and PGF 2␣ synthesis, while the administration of PGF 2␣ to ␣2AP-deficient mice facilitated ␣2AP deficiency-attenuated fibrosis.Conclusion. These findings suggest that ␣2AP regulates the development of fibrosis by PGF 2␣ synthesis through ATGL/iPLA 2 . The inhibition of ␣2AP-initiated pathways might provide a novel therapeutic approach to fibrotic diseases.